Home Newsfeeds NeuroMetrix Granted European Patent ‘Smart Electrode Assembly For Transcutaneous Electrical Nerve Stimulation’

NeuroMetrix Granted European Patent ‘Smart Electrode Assembly For Transcutaneous Electrical Nerve Stimulation’

https://twitter.com/PatentGrants/status/1544740557804580864

byBill Haddad

July 6, 2022

1 minute read

$NURO NeuroMetrix has been granted European patent number EP3558446 titled "SMART ELECTRODE ASSEMBLY FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION". https://t.co/6cVAAWbNoN

— PatentGrants (@PatentGrants) July 6, 2022

Evolus Enters Into Licensing Agreement With Symatese To Exclusively Distribute Next-Generation Dermal Fillers In Europe; Evolus Will Pre-Announce Preliminary, Unaudited Q4 And FY23 Results And Revenue Guidance For 2024 In January

By Benzinga Newsdesk

December 20, 9:04 AM

Exclusive Distributor Agreement with Symatese Broadens Evolus' Dermal Filler Footprint Beyond the U.S. to Include the United Kingdom and EuropeEuropean Regulatory Approvals Anticipated in Second Half of 2024Company

EOLS

Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac

By Vandana Singh

December 7, 9:35 AM

U.S. District Judge Robin Rosenberg in Florida has dismissed about 50,000 claims associated with GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), Sanofi SA (NASDAQ:SNY), and Boehringer Ingelheim, claiming…

GSK

Healthcare Insurance Giant Humana Stock Hits 52-Week Low Today – Here’s Why

By Vandana Singh

January 18, 8:41 AM

Humana revises fiscal 2023 earnings outlook, citing higher-than-expected healthcare costs. 2023 adjusted earnings now at $26.09/share, down from earlier forecast of $28.25/share.

CVS

Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People

By Vandana Singh

July 17, 12:20 PM

Virios Therapeutics Inc (NASDAQ: VIRI) announced that female patients diagnosed with Long-COVID illness exhibited clinically and statistically significant improvements related to Long-COVID when treated open-label with a combination of valacyclovir and celecoxib (Val/Cel) for 14 weeks,

VIRI

NeuroMetrix Granted European Patent ‘Smart Electrode Assembly For Transcutaneous Electrical Nerve Stimulation’

Related Posts

Evolus Enters Into Licensing Agreement With Symatese To Exclusively Distribute Next-Generation Dermal Fillers In Europe; Evolus Will Pre-Announce Preliminary, Unaudited Q4 And FY23 Results And Revenue Guidance For 2024 In January

Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac

Healthcare Insurance Giant Humana Stock Hits 52-Week Low Today – Here’s Why

Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People